The Radboud university medical center will start an experimental treatment with a vaccine that reduces the risk of the recurrence of skin cancer. The therapy activates the immune system and is intended for skin cancer patients for whom recently the lymph nodes with cancer metastases have been removed.
The study will last until 2021 and up to 20 million euros will be paid during that period from the basic health insurance. The treatment will be offered in Nijmegen, Amsterdam, Rotterdam and Zwolle and is led by Jolanda de Vries, theme Cancer development and immune defense
(only in Dutch)